Wellness brand Maxine+Morgan is launching a clinical study to investigate the effectiveness of its custom herbal blend of CBD, turmeric, ginger and other natural ingredients for menstrual symptom relief.
In a three-month long, blind placebo-controlled study, participants will record their pain levels and quality of life twice a day.
At random, the 70 participants will receive a Maxine+Morgan herbal supplement, Ibuprofen, and placebo in order to compare results.
"With the clinical study, we're hoping to continue the conversation around women's wellness and ways in which we can use the amazing healing qualities of naturally derived herbs to influence an uninterrupted lifestyle,” Ariel Morgan, CEO and president of Maxine+Morgan, told Benzinga. “It's important to us that we leverage our resources and invest in research, analysis and experiential data to efficiently support our consumers needs.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Click on the image for more info.
Cannabis rescheduling seems to be right around the corner
Want to understand what this means for the future of the industry?
Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9.
Get your tickets now before prices surge by following this link.